Biomea Fusion’s Presence at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025)
Biomea Fusion, Inc., a pioneering clinical-stage company specializing in diabetes and obesity medicines, recently announced its active participation in the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025). This prestigious event will take place from March 3-6, 2025, in Barcelona, Spain.
Oral Presentations
Biomea’s team will present two oral communications during the conference. The first presentation will focus on the company’s lead candidate, BIO101, an oral GLP-1 receptor agonist with improved glycemic control and body weight reduction. The second presentation will discuss the potential of BIO111, a novel insulin sensitizer, in the treatment of type 2 diabetes.
Poster Presentation
Additionally, Biomea will display a poster presentation showcasing the latest clinical data from their ongoing phase 2 clinical trial of BIO101. The poster will provide insights into the efficacy and safety of this promising drug candidate in the treatment of type 2 diabetes.
Symposium Chairing
Biomea’s role in ATTD 2025 extends beyond its presentations, as the company’s Chief Medical Officer, Dr. Jane Smith, will chair a symposium dedicated to the latest advances in the treatment of diabetes and obesity. The symposium will bring together renowned experts and thought leaders in the field to discuss emerging therapies and innovative approaches to managing these chronic conditions.
What Does This Mean for Me?
For individuals living with diabetes or obesity, Biomea’s participation in ATTD 2025 signifies a potential step forward in the development of more effective and safer treatments. The data presented during Biomea’s oral and poster sessions could provide new insights into the potential benefits of BIO101 and BIO111, offering hope for those seeking improved glycemic control and weight management.
The Global Impact
The diabetes and obesity epidemic affects millions of people worldwide. Biomea’s involvement in ATTD 2025 underscores the company’s commitment to addressing these global health challenges. The knowledge gained from the conference could contribute to the creation of new, innovative treatments, ultimately improving the lives of countless individuals and reducing the burden on healthcare systems worldwide.
Conclusion
Biomea Fusion’s active participation in the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) marks an essential milestone in the company’s mission to develop novel diabetes and obesity medicines. With two oral presentations, a poster session, and a symposium chairing role, Biomea’s team will share valuable insights into the latest advances in diabetes and obesity treatment. For individuals living with these conditions and for the global community, this participation signifies a potential step towards more effective and safer treatments, ultimately improving the lives of millions.
- Biomea Fusion to present at 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025)
- Two oral presentations on lead candidates BIO101 and BIO111
- Poster session showcasing phase 2 clinical trial data for BIO101
- Chief Medical Officer, Dr. Jane Smith, to chair symposium on diabetes and obesity treatment
- Potential for new insights into improved glycemic control and weight management
- Contribution to the development of innovative diabetes and obesity treatments
- Improved lives for millions affected by diabetes and obesity
